Cite
HARVARD Citation
Riganti, C. et al. (2018). Bromodomain inhibition exerts its therapeutic potential in malignant pleural mesothelioma by promoting immunogenic cell death and changing the tumor immune-environment. Oncoimmunology. p. . [Online].